A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

BACKGROUND: Human hepatocellular carcinoma (HCC) cells are largely deficient of argininosuccinate synthetase and thus auxotrophic for arginine. This study aims to investigate the efficacy and pharmacodynamics of pegylated arginine deiminase (ADI-PEG 20), a systemic arginine deprivation agent, in Asi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yang, T-S, Lu, S-N, Chao, Y, Sheen, I-S, Lin, C-C, Wang, T-E, Chen, S-C, Wang, J-H, Liao, L-Y, Thomson, J A, Wang-Peng, J, Chen, P-J, Chen, L-T
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2010
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2965867/
https://ncbi.nlm.nih.gov/pubmed/20808309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605856
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi